Presentation and outcome of gastrointestinal involvement in hepatitis C virus-related systemic vasculitis: a case–control study from a single-centre cohort of 163 patients
Abstract
Background During primary systemic vasculitides gastrointestinal (GI) involvement is associated with a poor outcome, leading to the use of immunosuppressive therapy. The significance of GI involvement during hepatitis C virus (HCV)-related systemic vasculitis has never been evaluated. Objective To evaluate the significance of GI involvement during HCV-related systemic vasculitis in the antiviral therapy era. Methods Data from 163 patients were retrospectively reviewed to describe the presentation and outcome of patients with HCV-related systemic vasculitis with GI involvement (GI+), and to compare them with patients without GI involvement (GI−). Results GI manifestations were present in 12 (7.4%) patients. Abdominal pain was consistently present in GI+ patients, and half of patients presented with surgical abdomen and/or intestinal bleeding. GI+ compared to GI− patients had more frequent renal (75% vs 30%; p=0.003) and cardiac involvement (25% vs 2%; p=0.006), medium-vessel vasculitis (67% vs 22%; p=0.003) and higher mixed cryoglobulinaemia levels (2.2 g/l vs 1.2 g/l; p=0.07). After treatment, GI+ and GI− patients had similar rates of overall clinical response of the vasculitis and immunological and virological responses. HCV-MC vasculitis patients with GI involvement did not have poorer overall survival than those without. Conclusion GI involvement is a rare manifestation of HCV-related vasculitis, associated with acute-onset and life-threatening manifestations. In contrast with primary vasculitides, GI+ patients do not seem to have poorer overall survival than GI− patients.Keywords
This publication has 26 references indexed in Scilit:
- Efficacy and tolerability of rituximab with or without PEGylated interferon alfa‐2b plus ribavirin in severe hepatitis C virus–related vasculitis: A long‐term followup study of thirty‐two patientsArthritis & Rheumatism, 2009
- Antiviral therapy for hepatitis C virus–associated mixed cryoglobulinemia vasculitis: A long‐term followup studyArthritis & Rheumatism, 2006
- Interferon‐α and ribavirin treatment in patients with hepatitis C virus–related systemic vasculitisArthritis & Rheumatism, 2002
- Hepatitis C virus infection and vasculitis: Implications of antiviral and immunosuppressive therapiesArthritis & Rheumatism, 2002
- Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: Analysis of four prospective trials including 278 patientsArthritis & Rheumatism, 2001
- Extrahepatic manifestations of chronic hepatitis CArthritis & Rheumatism, 1999
- Mixed cryoglobulinemia and hepatitis C virusThe American Journal of Medicine, 1994
- Antibodies to hepatitis C virus in patients with mixed cryoglobulinemiaArthritis & Rheumatism, 1991
- The American college of rheumatology 1990 criteria for the classification of polyarteritis nodosaArthritis & Rheumatism, 1990
- Mixed cryoglobulinemia: Clinical aspects and long-term follow-up of 40 patientsThe American Journal of Medicine, 1980